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Synopsis
This study compares APT-CEST between pre- and post-gadolinium in patients with gliomas at 3T, and evaluates the feasibility of performing
CEST after administration of T1 contrast. The results of the study demonstrate that Gd administration does not significantly aﬀect the
quality of the APT-CEST image, encouraging the acquisition of CEST data, even after the administration of T1 contrast agents.
Introduction
In the last few years, chemical exchange saturation transfer (CEST) imaging has emerged as a metabolic marker for MRI, with great promise in the
field of neuro-oncology. APT-CEST has shown to correlate with tumour grading  as well as to provide useful clinical information such as diﬀerentiation
of radiation necrosis from tumour recurrence . Tissue relaxation can alter APT-CEST contrast and as such the recommendation is to perform it prior
the administration of contrast agent  However, this can be practically diﬃcult as clinical exams tend to be prioritised over changes in protocol for
research. Some MRI vendors require modification of the scanner software to run CEST sequences, which further complicates the inclusion of CEST
half way through the clinical exam. This study compares APT-CEST between pre- and post-gadolinium in patients with gliomas at 3T, and evaluates
the feasibility of performing CEST after administration of T1 contrast.
Methods
Patients: Seven patients with suspected glioma were recruited with inform consent for APT-CEST pre- and post- Gadolinium (Gd). Three patients
underwent follow up imaging with a total of 11 studies included for analysis. Volunteers: Nine healthy volunteers were also recruited to assess
repeatability of APT within subjects. Time between APT-CEST scans was identical as in patients but no Gd was administrated. All studies were
conducted on a Siemens mMR biograph. APT-CEST was acquired with a gradient echo based snapCEST acquisition , where a 3s (50% duty cycle)
was used at two diﬀerent powers (B1 = 0.75, 1.25μT) for B1 correction. A WASAB1 scan  was also acquired for field homogeneity corrections. APT-
CEST was calculated as the normalised asymmetry at 3.5ppm and corrected for both B0 and B1 field inhomogeneity . T1 maps were acquired with
an inversion recovery method (TI=0.1s, 0.235s, 0.550s, 1.3s, 3s and 7s, TR=10s) using the same readout as for APT-CEST. Analysis: In patients,
regions of interest (ROI) of the ‘non-enhancing’, ‘enhancing’ and ‘necrotic core’ in the tumour and healthy ‘white matter’ (WM), were segmented from
T2w-FLAIR and T1w-postGd images (Figure 1). In volunteer subjects WM was segmented from the T2w-FLAIR. For all ROIs, APT-CEST signal was
compared pre- and post- Gd. Bland Altman plots and histogram analysis was performed for both APT-CEST and quantitative T1 maps. In order to
assess the eﬀect of Gd in APT-CEST, the normal variation was estimated from the healthy volunteer cohort.
Results
Pre- and post- Gd APT-CEST images displayed very similar features, highlighting the same areas of the brain in both scans. The range of contrast in
diﬀerent gliomas that APT- CEST was able to produce remained mostly unaﬀected post administration of Gd as seen in figure 1. ROI based
histogram analysis in figure 2 illustrates the variation pre- and post- contrast in the APT-CEST. All ROIs (in rows) show extensive overlap between the
two time-points. Pairwise t-test on the mean signal of each patient in diﬀerent ROIs revealed no significant diﬀerence (p>0.05) in the core, non-
enhancing and WM regions. Low significant diﬀerence (p<0.05) was found in the enhancing tumour region (row 2). A near identity (1:1) correlation was
found between the pre- and post- Gd APT-CEST scans (y=1.07x+0.00, r2 = 0.96, n= 43) as shown in figure 3 (left). Based on the contrast required to
diﬀerentiate WM versus non-enhancing lesions, the ‘maximum allowed diﬀerence’ for APT was set at ±0.005. With this limit the Bland-Altman plot
(figure 3, right) shows a 95% agreement between pre- and post scans (41 out of 43 points). Healthy volunteers display the same degree of variation
as patients with Gd administration. In contrast, the scatter plot of the quantitative T1 (figure 4), show both enhancing and core regions to be severely
biased due to the Gd administration with a mean diﬀerence of 700ms.
Discussion and Conclussion
The consistency of the APT-CEST even in regions with significant T1 reduction post Gd, supports the idea that the APT signal originates mostly from
the intracellular volume, where Gd does not permeate. Further quantitative analysis would need to account for the blood volume (an interstitial space
in cases of blood brain barrier leakage) in order to accurately estimate the impact of Gd in the APT contrast. Nonetheless, the results of this study
demonstrate that Gd administration does not significantly aﬀect the quality of the APT-CEST image, encouraging the acquisition of CEST data, even
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Figures
Figure 1: Pre- and post-Gd APT-CEST and T1w images of four patients (left). APT-CEST and T1w images of two healthy volunteers. Time between 1st
and 2nd ATP scans was the same as in patients, but no Gd was administrated (right)..
Figure 2 Histograms of the APT-CEST signal pre-(in green) and post-Gd (red) in 5 diﬀerent patients for all the segmented ROIs. Columns represent
diﬀerent patients. Each row corresponds to diﬀerent ROI. Bottom row displays the histogram in the WM ROI for 5 healthy volunteers with no Gd
between the two scans.
Figure 3: Correlation and Bland-Altman plot of the pre- and post-Gd APT-CEST signal for all ROIs and participants. Volunteer subjects (shown as
diamonds in the graph) did not have Gd injection.
Figure 4: Correlation and Bland-Altman plot of the pre- and post-Gd T1 values for all ROIs and participants. Volunteer subjects (shown as diamonds
in the graph) did not have Gd injection.
